| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
MIF DNA vaccine shows a preventive and therapeutic effect in a number of models of inflammations, including enteritis. For induction of anti-MIF auto-antibody, the vaccine incorporates a helper T epitope, a peptide fragment (TTX) from the tetanus toxin. In the present study, a new series of MIF vaccine were prepared that employed epitopes from ovalbumin (OVA), egg white lysozyme (HEL), and tetanus toxin (TET830). On the other hand, it has been confirmed that, in inflammation-induced colon cancer model, the expression of various cytokines (IL-4, IL-17a, GM-CSF), chemokines (CCL12, CCL20) and MMP3 is concord with that of MIF. Upon inoculation with the initial type MIF-DNA vaccine, carcinogenesis inhibitory effect could be confirmed with good reproducibility.
|
